Ionis Pharmaceuticals reduced its 2026 Tryngolza (olezarsen) sales outlook to approximately $50 million, from a previous range of $100 million–$110 million, citing a slower-than-expected launch in severe hypertriglyceridemia. The company separately reported $37 million in third-quarter revenue for Dawnzera and maintained its full-year guidance for that product. Ionis also began the commercial launch of Zanvastro for Alexander disease, while reaffirming broader company guidance. Its shares fell approximately 29% following the announcement.
SEC+1
Primary source: Ionis financial results, November 9
Why it matters strategically
Regulatory approval and successful clinical development do not guarantee rapid market adoption.
For specialty medicines, diagnosis, prescriber behavior, payer authorization, and the definition of eligible patients can constrain revenue even when the therapeutic rationale is compelling.
